-
Company Insights
NewElevance Health – Digital Transformation Strategies
Elevance Health Digital Transformation Strategies Overview Elevance Health is tapping the power of big data analytics to analyze data and generate insights, improve member engagement, and detect fraudulent claims. AI, big data, cloud, and automation are among the key technologies under focus for the company. The annual ICT spending of Elevance Health was estimated at $3.8 billion in 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. Elevance Health Inc...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Refractory Acute Myeloid Leukemia Drug Details: Actimab-A (HuM195-Ac-225)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Relapsed Acute Myeloid Leukemia Drug Details: Actimab-A (HuM195-Ac-225)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Chronic Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Multiple Myeloma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Diffuse Large...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iodine I 131 Apamistamab in Follicular Lymphoma Drug Details:...
-
Company Insights
The Emirates Group – Digital Transformation Strategies
Emirates Digital Transformation Strategies Overview Emirates is leveraging several emerging technologies as a part of its digital transformation strategies. The annual ICT spending of Emirates was estimated at $819 million in 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. The Emirates Group (Emirates Group) provides domestic, regional, and international air transportation services. The company’s other operations include wholesale and retail of consumer goods, food and beverage sales, and hotel...
-
Company Insights
Expedia Group Inc. – Digital Transformation Strategies
Expedia Digital Transformation Strategies Overview Expedia Group, Inc. (Expedia Group) is implementing innovative technologies to enhance its operations and provide better customer service. AI, cloud, digital payments, and virtual and augmented reality are among the key technologies under focus for the company. The annual ICT spending of Expedia is estimated at $729.6 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, networks, and communications from vendors. Expedia is a US-based online travel company operating...